Editorial: Drug-induced liver injury in clinical trials: As rare as hens teeth

American Journal of Gastroenterology

Volumn 104, Issue 5, 2009, Pages 1159-1161

  Davern, Timothy J ^a   Chalasani, Naga ^b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BROMFENAC; CYTOCHROME P450 2C8; DICLOFENAC; DICLOFENAC POTASSIUM; ETORICOXIB; GLUCURONOSYLTRANSFERASE 2B7; IBUPROFEN; NAPROXEN; XIMELAGATRAN; DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; DRUG MONITORING; FATIGUE; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; INCIDENCE; JAUNDICE; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; NAUSEA; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SIDE EFFECT; VIRUS HEPATITIS; VOMITING; CHEMICALLY INDUCED DISORDER; FEMALE; HOSPITALIZATION; LIVER DISEASE; MALE; NOTE; PATHOLOGY; RARE DISEASE; RISK ASSESSMENT; SURVIVAL RATE;

CLINICAL TRIALS AS TOPIC; DICLOFENAC; FEMALE; HUMANS; INCIDENCE; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; PHARMACEUTICAL PREPARATIONS; RARE DISEASES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 66949121802     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.76     Document Type: Review

References (12)

1. Ostapowicz G, Fontana RJ, Schiødt FV et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-54.
2. Fontana RJ, McCashland TM, Benner KG et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg 1999;5:480-4.
3. Aithal GR Day CP. Nonsteroidal anti-inflammatory drug-induced hepato-toxicity. Clin Liver Dis 2007;11:563-75.
4. Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993;38:744-51.
5. Banks AT, Zimmerman HJ, Ishak KG et al. Diclofenac-associated hepato-toxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995;22:820-7.
6. Daly AK, Aithal GR Leathart JB et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007;132:272-81.
7. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003;192:307-22.
8. Laine L, Goldkind L, Curtis SP et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 2009;104:356-62.
9. Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis 2007;11:507-24.
10. Harris MP, Hasso SM, Ferguson MW et al. The development of archosaurian first-generation teeth in a chicken mutant. Curr Biol 2006;16:371-7.
11. Lee WM, Larrey D, Olsson R et al. Hepatic findings in long-term clinical trials of ximelagatran. DrugSaf 2005;28:351-70.
12. Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 2004;40:773.